Stocksigma LogoStocksigma Logo

Sun Pharma's UNLOXCYT Receives NCCN Category 2A Recommendation for Advanced Skin Cancer

Sun Pharma announced on 20th Oct'26 that UNLOXCYT (cosibelimab-ipdl) has received an NCCN Category 2A recommendation for locally advanced cutaneous

Sun Pharma's UNLOXCYT Receives NCCN Category 2A Recommendation for Advanced Skin Cancer

Sun Pharmaceutical Industries Ltd 路 Press Release 路 20 Oct 2026, 11:03 pm

Sun Pharma's UNLOXCYT Receives NCCN Category 2A Recommendation for Advanced Skin Cancer Sun Pharma announced on 20th Oct'26 that UNLOXCYT (cosibelimab-ipdl) has received an NCCN Category 2A recommendation for locally advanced cutaneous squamous cell carcinoma (laCSCC) in patients ineligible for curative surgery or radiation, complementing its existing '25 mCSCC designation. Pivotal trial data demonstrated a 55% objective response rate, 26% complete response rate, and under 1% high-grade immune-mediated adverse reactions, with median duration of response unreached at 24.1 months follow-up. This updated guideline designation is expected to strengthen institutional formulary adoption, payer coverage, and upfront patient access across the US.

Original exchange filing (PDF)

More announcements from Sun Pharmaceutical Industries Ltd

All Sun Pharmaceutical Industries Ltd announcements